Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic

J Rheumatol. 2020 Jun 1;47(6):783-786. doi: 10.3899/jrheum.200369. Epub 2020 Apr 2.

Authors

Rosie Scuccimarri¹, Evelyn Sutton², Mary-Ann Fitzcharles³

Affiliations

¹ Division of Pediatric Rheumatology, McGill University Health Centre, Montreal, Quebec, and Chair, Canadian Rheumatology Association (CRA) Therapeutics Committee.
² Division of Rheumatology, Dalhousie University, Halifax, Nova Scotia, and President, CRA.
³ Alan Edwards Pain Management Unit, Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada, and Past Chair, CRA Therapeutics Committee. mfitzcharles@sympatico.ca.

PMID: 32241801
DOI: 10.3899/jrheum.200369

No abstract available

Publication types

Editorial

MeSH terms

Antirheumatic Agents / therapeutic use*
Betacoronavirus
COVID-19
Coronavirus Infections / diagnosis
Coronavirus Infections / drug therapy*
Female
Health Knowledge, Attitudes, Practice*
Humans
Hydroxychloroquine / therapeutic use*
Male
Pandemics / prevention & control
Pandemics / statistics & numerical data*
Pneumonia, Viral / diagnosis
Pneumonia, Viral / drug therapy*
Prognosis
Rheumatologists / ethics*
Risk Assessment
SARS-CoV-2
Treatment Outcome

Substances

Antirheumatic Agents
Hydroxychloroquine